VRCDF (Verici Dx) FCF Margin % : -97.99% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Verici Dx's Free Cash Flow for the six months ended in Jun. 2024 was $-3.27 Mil. Verici Dx's Revenue for the six months ended in Jun. 2024 was $3.34 Mil. Therefore, Verici Dx's FCF Margin % for the quarter that ended in Jun. 2024 was -97.99%.

As of today, Verici Dx's current FCF Yield % is -57.87%.

The historical rank and industry rank for Verici Dx's FCF Margin % or its related term are showing as below:

VRCDF' s FCF Margin % Range Over the Past 10 Years
Min: -729.75 Med: -729.75 Max: -133.65
Current: -133.65

During the past 4 years, the highest FCF Margin % of Verici Dx was -133.65%. The lowest was -729.75%. And the median was -729.75%.

VRCDF's FCF Margin % is ranked worse than
87.26% of 212 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.335 vs VRCDF: -133.65

Verici Dx FCF Margin % Historical Data

The historical data trend for Verici Dx's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx FCF Margin % Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-729.62

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial			-	-	-25,642.11	-253.42	-97.99

Competitive Comparison of Verici Dx's FCF Margin %

For the Diagnostics & Research subindustry, Verici Dx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Verici Dx's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Verici Dx FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Verici Dx's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-7.391	/	1.013
	=	-729.62 %

Verici Dx's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-3.272	/	3.339
	=	-97.99 %

Verici Dx FCF Margin % Related Terms

Thank you for viewing the detailed overview of Verici Dx's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines